The US Food and Drug Administration’s phased roll out of its “integrated assessment” of drug and biological license applications has gained momentum as more than 30 marketing applications have gone through the new review process and another three dozen or so are currently undergoing this assessment.
The integrated assessment differs from the standard summary review as it involves an interdisciplinary, collaborative approach to discuss key regulatory...








